TNF Pharmaceuticals Delivers Platform Presentation of Oral TNF-Alpha Inhibitor Isomyosamine at British Geriatrics Society's Spring Meeting 2025
BALTIMORE--(BUSINESS WIRE)--Apr 16, 2025--
TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) ('TNF' or the 'Company'), a clinical stage biopharmaceutical company committed to developing novel therapies for autoimmune and inflammatory conditions, announced today that a platform presentation of an abstract titled 'Isomyosamine for the Treatment of Sarcopenia in Older Adults' was delivered by Mitchell Glass, M.D., President and Chief Medical Officer of TNF, at the British Geriatrics Society (BGB) Spring Meeting 2025, held April 9-11, 2025, in Belfast, Ireland and online.
During his presentation, Dr. Glass spoke about the Company's small-molecule TNF-alpha (TNF-α) inhibitor, isomyosamine, which has shown potential for regulating pro-inflammatory cytokines associated with sarcopenia. In response to a question, he emphasized the Company's commitment to sarcopenia as an initial indication, including muscle wasting as an effect of treatment with GLP-1 agonists. He also commented on the Company's plans to extend Phase 3 into the UK and Europe.
'An earlier Phase 2 study of isomyosamine demonstrated its safety and tolerability in elderly patients with sarcopenia, with significant reductions in inflammatory biomarkers such as TNF-α, IL-6, and soluble TNF receptor 1 (sTNFR1). We are currently enrolling patients in a larger Phase 2b clinical trial that will investigate isomyosamine's effect on cellular inflammation and recovery of ambulation speed in elderly patients post-hip fracture. An increased sample size and more frequent dosing in the follow-up trial will enable us to better evaluate the drug's potential to improve both clinical and biochemical outcomes in sarcopenic patients,' Dr. Glass explained.
The British Geriatrics Society is the membership association for professionals specializing in the healthcare of older people across the UK. Founded in 1947, BGS has over 5,000 members, and it is the only Society in the UK offering specialist expertise in the wide range of healthcare needs of older people.
About Isomyosamine
Isomyosamine (ICD-10-CM code M62.84) is a novel plant alkaloid small molecule shown to regulate the immuno-metabolic system through the modulation of numerous pro-inflammatory cytokines including TNF-alpha (TNF-α), an immune cell signaling protein and inflammatory cytokine responsible for inducing and maintaining the inflammatory process. TNF-α is located upstream of a cascade of molecular signals that induces inflammation and helps activate the process of aging. Many in vivo and in vitro studies have shown that TNFα plays a causative role in the pathogenesis of various age-related diseases.
About TNF Pharmaceuticals, Inc.
TNF Pharmaceuticals, Inc. (Nasdaq: TNFA), a clinical stage pharmaceutical company committed to extending healthy lifespan, is focused on developing two novel therapeutic platforms that treat the causes of disease rather than only addressing the symptoms. Isomyosamine is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-α, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. Isomyosamine is being developed to treat diseases and disorders marked by acute or chronic inflammation. The Company's second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction and epilepsy. Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve upon the rapidly growing CBD market, which includes both FDA approved drugs and CBD products not currently regulated as drugs. For more information, visit www.tnfpharma.com.
Cautionary Statement Regarding Forward-Looking Statements
This press release may contain forward-looking statements. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements to be materially different from any expected future results, performance, or achievements. Forward-looking statements speak only as of the date they are made and neither the Company nor its affiliates assume any duty to update forward-looking statements. Words such as 'anticipate,' 'believe,' 'could,' 'estimate,' 'expect,' 'may,' 'plan,' 'will,' 'would'' and other similar expressions are intended to identify these forward-looking statements. Examples of such statements include, but are not limited to, statements regarding the Company's ability to launch and the timing of the Company's planned trial of isomyosamine as a treatment for GLP-1-induced sarcopenia and frailty. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, without limitation: the Company's ability to maintain compliance with the Nasdaq Stock Market's listing standards; the timing of, and the Company's ability to, obtain and maintain regulatory approvals for clinical trials of the Company's pharmaceutical candidates; the timing and results of the Company's planned clinical trials for its pharmaceutical candidates; the amount of funds the Company requires for its pharmaceutical candidates; increased levels of competition; changes in political, economic or regulatory conditions generally and in the markets in which the Company operates; the Company's ability to retain and attract senior management and other key employees; the Company's ability to quickly and effectively respond to new technological developments; and the Company's ability to protect its trade secrets or other proprietary rights, operate without infringing upon the proprietary rights of others and prevent others from infringing on the Company's proprietary rights. A discussion of these and other factors with respect to the Company is set forth in the Company's Annual Report on Form 10-K for the year ended December 31, 2024, filed by the Company on April 11, 2025, and subsequent reports that the Company files with the Securities and Exchange Commission. Forward-looking statements speak only as of the date they are made, and the Company disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise.
View source version on businesswire.com:https://www.businesswire.com/news/home/20250416886460/en/
CONTACT: Investor Contact:Robert Schatz
(646) 421-9523
[email protected]
www.tnfpharma.com
KEYWORD: NORTH AMERICA UNITED STATES IRELAND UNITED KINGDOM EUROPE MARYLAND
INDUSTRY KEYWORD: RESEARCH SENIORS CLINICAL TRIALS OTHER HEALTH BIOTECHNOLOGY GENERAL HEALTH PHARMACEUTICAL CONSUMER HEALTH SCIENCE
SOURCE: TNF Pharmaceuticals, Inc.
Copyright Business Wire 2025.
PUB: 04/16/2025 09:15 AM/DISC: 04/16/2025 09:16 AM
http://www.businesswire.com/news/home/20250416886460/en
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
43 minutes ago
- Yahoo
Casey's Tops Estimates, Boosts Dividend
Casey's General Stores posted 11% revenue and 12% earnings-per-share growth in the quarter, surpassing Wall Street estimates. The company's results were aided by the acquisition of Fikes Wholesale, but Casey's managed to post inside same-store sales growth despite a tough operating environment. Casey's boosted its quarterly dividend for the 26th consecutive year and provided an initial forecast for growth in its new fiscal year. 10 stocks we like better than Casey's General Stores › Here's our initial take on Casey's General Stores' (NASDAQ: CASY) financial report. Metric Q4 FY24 Q4 FY25 Change vs. Expectations Revenue $3.60 billion $3.99 billion 11% Beat Earnings per share $2.34 $2.63 12% Beat Inside same-store sales +5.6% +1.7% -390 bp n/a Gross margin 41.2% 41.2% n/c n/a Convenience store powerhouse Casey's General Stores capped off a strong fiscal 2025, reporting double-digit quarterly revenue and earnings growth that topped expectations. The company is holding up better than a lot of retailers in a tough environment, with growth being driven by strong results from its bakery and hot sandwich offerings and from nonalcoholic beverages. Inside same-store sales grew by just 1.7% in the quarter, but CEO Darren Rebelez said that the full-year 2.6% growth "outperformed the industry." Casey's is also doing a good job of keeping a handle on costs, reducing same-store labor hours for the 12th consecutive quarter. Overall inside margin held steady year over year, with a slight uptick in grocery margin offset by a slight decrease in prepared food margin. This was a year of growth for Casey's. The company grew its store count from 2,658 to 2,904 over the past year, including about 35 new builds, as well as through its $1.1 billion acquisition of Fikes Wholesale, Casey's largest deal to date. Casey's continues to return more cash to shareholders. The company raised its quarterly dividend by 14% to $0.57 per share, marking the 26th consecutive annual increase. Investors seemed to like what Casey's was serving. The company's stock was up more than 7% immediately following the earnings release but ahead of Tuesday morning's planned call with investors. This is the end of Casey's fiscal year, and the company provided its first outlook for what it expects in the 12 months ahead. Casey's is forecasting that inside same-store sales will grow by 2% to 5% in fiscal 2026 and that EBITDA will grow by 10% to 12%. Casey's expects to continue to grow, forecasting it will open at least 80 stores via a combination of new construction and acquisitions, continuing on its three-year plan to expand by about 500 stores. This is a company that has been able to successfully apply its winning formula to new locations through both organic growth and M&A. It is a tough market for retail right now, but Casey's remains a standout. Full earnings report Investor relations page Before you buy stock in Casey's General Stores, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Casey's General Stores wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $669,517!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $868,615!* Now, it's worth noting Stock Advisor's total average return is 792% — a market-crushing outperformance compared to 173% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 Lou Whiteman has no position in any of the stocks mentioned. The Motley Fool recommends Casey's General Stores. The Motley Fool has a disclosure policy. Casey's Tops Estimates, Boosts Dividend was originally published by The Motley Fool Sign in to access your portfolio
Yahoo
44 minutes ago
- Yahoo
Sezzle Files Antitrust Action Against Shopify
Minneapolis, MN, June 09, 2025 (GLOBE NEWSWIRE) -- Sezzle Inc. (NASDAQ:) (Sezzle or Company) // Purpose-driven digital payment platform, Sezzle, announced today that it has filed a lawsuit against Shopify Inc. in the U.S. District Court for the District of Minnesota asserting federal and state antitrust violations. The lawsuit alleges that Shopify has been engaging and continues to engage in monopolistic and anticompetitive business practices in order to stifle competition for 'buy now, pay later' service options on Shopify's e-commerce platform. Sezzle is seeking an injunction to prevent Shopify from continuing its anticompetitive conduct that limits consumer choice and stifles fair market competition. The suit filed by the Company seeks treble damages. 'Sezzle remains committed to fostering a competitive, transparent, and consumer-friendly payments ecosystem,' stated Charlie Youakim, Sezzle Chairman and CEO. 'This action is an important step in ensuring that merchants and consumers have access to diverse and innovative payment solutions of their choice.' The Company also shared the following business updates: For the first quarter of 2025, revenue associated with gross merchandise volume attributable to Shopify's e-commerce platform represented less than 5.0% of Sezzle's total revenue. The Company is reaffirming its fiscal 2025 guidance, which was provided in its 1Q25 earnings release on May 7, 2025. Contact Information Lee Brading, CFA Investor Relations +1 651 240 6001 InvestorRelations@ Erin Foran Media Enquiries +1 651 403 2184 About Sezzle Inc. Sezzle is a forward-thinking fintech company committed to financially empowering the next generation. Through its purpose-driven payment platform, Sezzle enhances consumers' purchasing power by offering access to point-of-sale financing options and digital payment services—connecting millions of customers with its global network of merchants. Centered on transparency, inclusivity, and ease of use, Sezzle empowers consumers to manage spending responsibly, take charge of their finances, and achieve lasting financial independence. For more information visit Forward Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends affecting the financial condition of our business. Forward-looking statements include our expectations, whether stated or implied, regarding our financing plans and other future events. Forward-looking statements generally can be identified by the use of words such as "anticipate," "expect," "plan," "could," "may," "will," "believe," "estimate," "forecast," "goal," "project," other words or expressions of similar meaning (or the negative versions of such words or expressions). These forward-looking statements address various matters including statements regarding the timing or nature of future operating or financial performance or other events. Each forward-looking statement contained in this press release is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others: impact of the 'buy-now, pay-later' ('BNPL') industry becoming subject to increased regulatory scrutiny; impact of operating in a highly competitive industry; impact of macro-economic conditions on consumer spending; our ability to increase our merchant network, our base of consumers and gross merchandise value (GMV); our ability to effectively manage growth, sustain our growth rate and maintain our market share; our ability to maintain adequate access to capital in order to meet the capital requirements of our business; impact of exposure to consumer bad debts and insolvency of merchants; impact of the integration, support and prominent presentation of our platform by our merchants; impact of any data security breaches, cyberattacks, employee or other internal misconduct, malware, phishing or ransomware, physical security breaches, natural disasters, or similar disruptions; impact of key vendors or merchants failing to comply with legal or regulatory requirements or to provide various services that are important to our operations; impact of the loss of key partners and merchant relationships; impact of exchange rate fluctuations in the international markets in which we operate; our ability to protect our intellectual property rights and third party allegations of the misappropriation of intellectual property rights; our ability to retain employees and recruit additional employees; impact of the costs of complying with various laws and regulations applicable to the BNPL industry in the United States and Canada; and our ability to achieve our public benefit purpose and our election to forego our B Corporation certification and other factors identified in the 'Risk Factors' section of our Annual Report on Form 10-K for the year ended December 31, 2025 (the 'Annual Report') and the Company's subsequent filings filed with the SEC. You are encouraged to read the Company's Annual Report and other filings with the SEC, available at for a discussion of these and other risks and uncertainties.. The Company cautions investors not to place considerable reliance on the forward-looking statements contained in this press release. You are The forward-looking statements in this press release speak only as of the date of this document, and the Company undertakes no obligation to update or revise any of these statements. The Company's business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties. CONTACT: Erin Foran Sezzle 6514032184
Yahoo
an hour ago
- Yahoo
ReNew Announces Date and Conference Call Details for Fourth Quarter Earnings (Q4 FY25), Fiscal Year 2025 Results
GURUGRAM, India, June 09, 2025--(BUSINESS WIRE)--ReNew Energy Global plc ("ReNew") (NASDAQ: RNW, RNWWW), India's leading renewable energy company, today announced it will issue its fiscal fourth quarter (January - March) and year ended March 31, 2025, earnings report before the opening of the Nasdaq on June 16, 2025. A conference call has been scheduled to discuss the earnings results at 8:30 AM EST (6:00 PM IST) on June 16, 2025. The conference call can be accessed live at: or by phone (toll-free) by dialing: US/Canada: (+1) 855 881 1339France: (+33) 0800 981 498Germany: (+49) 0800 182 7617Hong Kong: (+852) 800 966 806India: (+91) 0008 0010 08443Japan: (+81) 005 3116 1281Singapore: (+65) 800 101 2785Sweden: (+46) 020 791 959UK: (+44) 0800 051 8245Rest of the world: (+61) 7 3145 4010 (toll) An audio replay will be available following the call on our investor relations website at About ReNew ReNew is a leading decarbonisation solutions company listed on Nasdaq (Nasdaq: RNW, RNWWW). ReNew's clean energy portfolio of ~17.4 GWs on a gross basis as of February 14, 2025, is one of the largest globally. In addition to being a major independent power producer in India, it provides end-to-end solutions in a just and inclusive manner in the areas of clean energy, value-added energy offerings through digitalisation, storage, and carbon markets that are increasingly integral to addressing climate change. For more information, visit and follow us on LinkedIn, Facebook, X, and Instagram. View source version on Contacts Press Enquiries pr@ Investor Enquiries ReNew | Anunay Shahi, Nitin Vaid | ir@
